Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Change in Cash (2022 - 2025)

TriSalus Life Sciences' Change in Cash history spans 4 years, with the latest figure at -$2.2 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 18.64% year-over-year to -$2.2 million; the TTM value through Dec 2025 reached $11.9 million, up 466.36%, while the annual FY2025 figure was $11.9 million, 466.36% up from the prior year.
  • Change in Cash reached -$2.2 million in Q4 2025 per TLSIW's latest filing, up from -$3.8 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $17.5 million in Q3 2023 to a low of -$17.8 million in Q3 2022.
  • Average Change in Cash over 4 years is -$594500.0, with a median of -$2.7 million recorded in 2022.
  • Peak YoY movement for Change in Cash: plummeted 15785.95% in 2023, then soared 536.99% in 2024.
  • A 4-year view of Change in Cash shows it stood at -$2.7 million in 2022, then tumbled by 255.5% to -$9.5 million in 2023, then soared by 70.93% to -$2.8 million in 2024, then rose by 18.64% to -$2.2 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Change in Cash are -$2.2 million (Q4 2025), -$3.8 million (Q3 2025), and $13.5 million (Q2 2025).